Effects of medical therapies on retinopathy progression in type 2 diabetes - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 Jul 15;363(3):233-44.
doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29.
ACCORD Eye Study Group; Emily Y Chew, Walter T Ambrosius, Matthew D Davis, Ronald P Danis, Sapna Gangaputra, Craig M Greven, Larry Hubbard, Barbara A Esser, James F Lovato, Letitia H Perdue, David C Goff Jr, William C Cushman, Henry N Ginsberg, Marshall B Elam, Saul Genuth, Hertzel C Gerstein, Ulrich Schubart, Lawrence J Fine
Collaborators
- PMID: 20587587
- PMCID: PMC4026164
- DOI: 10.1056/NEJMoa1001288
Randomized Controlled Trial
Effects of medical therapies on retinopathy progression in type 2 diabetes
ACCORD Study Group et al. N Engl J Med. 2010.
Erratum in
- N Engl J Med. 2011 Jan 13;364(2):190
- N Engl J Med. 2012 Dec 20;367(25):2458
Abstract
Background: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy.
Methods: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy.
Results: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29).
Conclusions: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
2010 Massachusetts Medical Society
Conflict of interest statement
No other potential conflict of interest relevant to this article was reported.
Figures
Figure 1. Subgroup Effects in the ACCORD Glycemia Trial
The estimated odds ratios for progression of diabetic retinopathy are indicated as squares (with the area proportional to the sample size). The vertical dashed line is the overall treatment effect. Data were missing for some patients in some subgroups. The comparison between the subgroup enrolled in the ACCORD Lipid trial and the subgroup enrolled in the ACCORD Blood-Pressure trial was not specified within the protocol. Race was self-reported. The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. A logarithmic scale is used on the x axis.
Figure 2. Subgroup Effects in the ACCORD Lipid Trial
The estimated odds ratios for progression of diabetic retinopathy are indicated as squares (with the area proportional to the sample size). The vertical dashed line is the overall treatment effect. Data were missing for some patients in some subgroups. Two comparisons were not specified within the protocol: the comparison between the subgroup with triglyceride levels of 204 mg per deciliter (2.3 mmol per liter) or higher and high-density lipoprotein (HDL) cholesterol levels of 34 mg per deciliter (0.9 mmol per liter) or less and the subgroup with lower triglyceride levels or higher HDL cholesterol levels, and the comparison between the subgroup with some retinopathy and the subgroup with none. Race was self-reported. The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129. LDL denotes low-density lipoprotein. A logarithmic scale is used on the x axis.
Figure 3. Subgroup Effects in the ACCORD Blood-Pressure Trial
The estimated odds ratios for progression of diabetic retinopathy are indicated as squares (with the area proportional to the sample size). The vertical dashed line is the overall treatment effect. Data were missing for some patients in some subgroups. The last four comparisons shown in the figure were not specified in the protocol. Race was self-reported. The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. A logarithmic scale is used on the x axis.
Comment in
- Reduction in risk of progression of diabetic retinopathy.
Klein BE. Klein BE. N Engl J Med. 2010 Jul 15;363(3):287-8. doi: 10.1056/NEJMe1005667. Epub 2010 Jun 29. N Engl J Med. 2010. PMID: 20587586 No abstract available. - ACP Journal Club. Intensifying glucose control and adding fenofibrate to simvastatin each reduced progression of retinopathy in type 2 diabetes.
Bronson DL. Bronson DL. Ann Intern Med. 2010 Nov 16;153(10):JC5-10. doi: 10.7326/0003-4819-153-10-201011160-02010. Ann Intern Med. 2010. PMID: 21079205 No abstract available. - Retinopathy progression in type 2 diabetes.
Rind DM. Rind DM. N Engl J Med. 2010 Nov 25;363(22):2172-3; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105806 No abstract available. - Retinopathy progression in type 2 diabetes.
Giral P, Rosenbaum D. Giral P, et al. N Engl J Med. 2010 Nov 25;363(22):2172; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105807 No abstract available. - Retinopathy progression in type 2 diabetes.
Baum SJ. Baum SJ. N Engl J Med. 2010 Nov 25;363(22):2172; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105808 No abstract available. - Retinopathy progression in type 2 diabetes.
Liew G, Wang JJ, Mitchell P. Liew G, et al. N Engl J Med. 2010 Nov 25;363(22):2171-2; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105809 No abstract available. - Retinopathy progression in type 2 diabetes.
Morita H, Nagai R. Morita H, et al. N Engl J Med. 2010 Nov 25;363(22):2171; author reply 2173-4. doi: 10.1056/NEJMc1009236. N Engl J Med. 2010. PMID: 21105810 No abstract available. - Update of the ACCORD Eye Study.
Chew EY, Ambrosius WT. Chew EY, et al. N Engl J Med. 2011 Jan 13;364(2):188-9. doi: 10.1056/NEJMc1011499. N Engl J Med. 2011. PMID: 21226603 No abstract available.
Similar articles
- The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT; Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group. Chew EY, et al. Ophthalmology. 2014 Dec;121(12):2443-51. doi: 10.1016/j.ophtha.2014.07.019. Epub 2014 Aug 29. Ophthalmology. 2014. PMID: 25172198 Free PMC article. Clinical Trial. - Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Diabetes Care. 2016 Jul;39(7):1089-100. doi: 10.2337/dc16-0024. Epub 2016 Jun 11. Diabetes Care. 2016. PMID: 27289122 Free PMC article. Clinical Trial. - Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE. Mottl AK, et al. Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693-1702. doi: 10.2215/CJN.06200518. Epub 2018 Oct 25. Clin J Am Soc Nephrol. 2018. PMID: 30361335 Free PMC article. Clinical Trial. - Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
Wright AD, Dodson PM. Wright AD, et al. Eye (Lond). 2011 Jul;25(7):843-9. doi: 10.1038/eye.2011.62. Epub 2011 Mar 25. Eye (Lond). 2011. PMID: 21436845 Free PMC article. Review. - Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM. Keating GM. Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 21675801 Review.
Cited by
- 2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories.
El Din Taha HS, Kandil H, Badran HM, Farag N, Khamis H, Nasr G, Samy M, Abdrabou M, Abuelezz M, Shaker MM. El Din Taha HS, et al. Egypt Heart J. 2024 Sep 20;76(1):131. doi: 10.1186/s43044-024-00562-7. Egypt Heart J. 2024. PMID: 39302613 Free PMC article. Review. - Short-Term Clinical Outcomes of Patients with Diabetic Macular Edema Following a Therapy Switch to Faricimab.
Wolfrum P, Böhm EW, Lorenz K, Stoffelns B, Pfeiffer N, Korb CA. Wolfrum P, et al. J Clin Med. 2024 Aug 1;13(15):4508. doi: 10.3390/jcm13154508. J Clin Med. 2024. PMID: 39124774 Free PMC article. - Impact of treatment cessation on incidence and progression of retinopathy in Japanese patients with type 2 diabetes mellitus: a retrospective cohort study.
Shinzato Y, Nakayama Y, Okamoto S, Millman JF, Uema T, Honma KI, Tamaki A, Uehara M, Teruya T, Yabiku T, Ishiki Y, Yonaha K, Arakaki KI, Higa M, Koizumi H, Nakamura K, Shimabukuro M, Masuzaki H. Shinzato Y, et al. Diabetol Int. 2024 May 5;15(3):535-543. doi: 10.1007/s13340-024-00724-7. eCollection 2024 Jul. Diabetol Int. 2024. PMID: 39101160 - 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.
Moon JS, Kang S, Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ, Seo JA, Kim MK, Lim JH, Song YJ, Yang YS, Kim JH, Lee YB, Noh J, Hur KY, Park JS, Rhee SY, Kim HJ, Kim HM, Ko JH, Kim NH, Kim CH, Ahn J, Oh TJ, Kim SK, Kim J, Han E, Jin SM, Bae J, Jeon E, Kim JM, Kang SM, Park JH, Yun JS, Cha BS, Moon MK, Lee BW. Moon JS, et al. Diabetes Metab J. 2024 Jul;48(4):546-708. doi: 10.4093/dmj.2024.0249. Epub 2024 Jul 26. Diabetes Metab J. 2024. PMID: 39091005 Free PMC article. No abstract available. - Lessons from PROMINENT and prospects for pemafibrate.
Fruchart JC, Fruchart-Najib J, Yamashita S, Libby P, Yokote K, Kodama T, Tomita Y, Ridker PM, Hermans MP, Zambon A. Fruchart JC, et al. Cardiovasc Diabetol. 2024 Jul 29;23(1):279. doi: 10.1186/s12933-024-02305-z. Cardiovasc Diabetol. 2024. PMID: 39080716 Free PMC article.
References
- Kempen JH, O’Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552–63. - PubMed
- The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113:36–51. - PubMed
- Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304–9. - PubMed
- Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17. - PubMed
- United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–53. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- ZIA EY000410-04/ImNIH/Intramural NIH HHS/United States
- N01HC95183/HC/NHLBI NIH HHS/United States
- Y01 HC001010/HC/NHLBI NIH HHS/United States
- N01HC95178/HC/NHLBI NIH HHS/United States
- N01-HC-95180/HC/NHLBI NIH HHS/United States
- Y01 HC009035/HC/NHLBI NIH HHS/United States
- IAA-Y1-HC-1010/HC/NHLBI NIH HHS/United States
- N01-HC-95183/HC/NHLBI NIH HHS/United States
- N01-HC-95178/HC/NHLBI NIH HHS/United States
- N01HC95182/HC/NHLBI NIH HHS/United States
- N01-HC-95179/HC/NHLBI NIH HHS/United States
- N01-HC-95181/HC/NHLBI NIH HHS/United States
- Z99 EY999999/ImNIH/Intramural NIH HHS/United States
- N01 HC095178/HC/NHLBI NIH HHS/United States
- N01-HC-95184/HC/NHLBI NIH HHS/United States
- R01 HL073030/HL/NHLBI NIH HHS/United States
- N01HC95180/HC/NHLBI NIH HHS/United States
- N01HC95181/HC/NHLBI NIH HHS/United States
- N01HC95184/HC/NHLBI NIH HHS/United States
- N01-HC-95182/HC/NHLBI NIH HHS/United States
- IAA-Y1-HC-9035/HC/NHLBI NIH HHS/United States
- N01HC95179/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical